CA2643736C - Methods and compositions to treat mucositis - Google Patents

Methods and compositions to treat mucositis Download PDF

Info

Publication number: CA2643736C
Authority: CA; Canada
Prior art keywords: peptide; administration; therapy; mucositis; protein
Prior art date: 2005-05-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2643736A

Other languages

English (en)

French (fr)

Other versions

CA2643736A1 (en

Inventor

F. Gary Toback

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Chicago

Original Assignee

University of Chicago

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-10

Filing date

2006-05-09

Publication date

2015-06-23

2005-05-10 Priority claimed from EP05010217A external-priority patent/EP1595547A3/de

2006-05-09 Application filed by University of Chicago filed Critical University of Chicago

2006-05-09 Priority claimed from PCT/US2006/018014 external-priority patent/WO2006122162A2/en

2006-11-16 Publication of CA2643736A1 publication Critical patent/CA2643736A1/en

2015-06-23 Application granted granted Critical

2015-06-23 Publication of CA2643736C publication Critical patent/CA2643736C/en

2026-05-09 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

206010028116 Mucosal inflammation Diseases 0.000 title claims abstract description 70
201000010927 Mucositis Diseases 0.000 title claims abstract description 70
239000000203 mixture Substances 0.000 title claims abstract description 24
238000000034 method Methods 0.000 title abstract description 19
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 178
238000011275 oncology therapy Methods 0.000 claims abstract description 12
108090000623 proteins and genes Proteins 0.000 claims description 62
102000004169 proteins and genes Human genes 0.000 claims description 62
230000005855 radiation Effects 0.000 claims description 30
125000003275 alpha amino acid group Chemical group 0.000 claims description 20
150000001413 amino acids Chemical class 0.000 claims description 18
239000008194 pharmaceutical composition Substances 0.000 claims description 17
238000002512 chemotherapy Methods 0.000 claims description 15
208000003265 stomatitis Diseases 0.000 claims description 15
238000001959 radiotherapy Methods 0.000 claims description 12
206010028980 Neoplasm Diseases 0.000 claims description 11
201000011510 cancer Diseases 0.000 claims description 11
238000002560 therapeutic procedure Methods 0.000 claims description 10
230000037396 body weight Effects 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
238000007911 parenteral administration Methods 0.000 claims description 7
238000007920 subcutaneous administration Methods 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 5
238000007912 intraperitoneal administration Methods 0.000 claims description 4
238000011200 topical administration Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
239000012634 fragment Substances 0.000 claims 4
101710205777 Gastrokine-1 Proteins 0.000 abstract description 68
102100035965 Gastrokine-1 Human genes 0.000 abstract description 68
102000004196 processed proteins & peptides Human genes 0.000 abstract description 46
241000124008 Mammalia Species 0.000 abstract description 9
101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 abstract description 4
230000001934 delay Effects 0.000 abstract description 4
102000049676 human GKN1 Human genes 0.000 abstract description 4
210000004027 cell Anatomy 0.000 description 77
235000018102 proteins Nutrition 0.000 description 54
230000000694 effects Effects 0.000 description 31
210000002919 epithelial cell Anatomy 0.000 description 30
238000011282 treatment Methods 0.000 description 25
230000006378 damage Effects 0.000 description 23
235000001014 amino acid Nutrition 0.000 description 22
210000001578 tight junction Anatomy 0.000 description 20
208000027418 Wounds and injury Diseases 0.000 description 19
208000014674 injury Diseases 0.000 description 19
241000699666 Mus <mouse, genus> Species 0.000 description 18
210000001035 gastrointestinal tract Anatomy 0.000 description 18
229940024606 amino acid Drugs 0.000 description 17
241000699670 Mus sp. Species 0.000 description 15
230000002496 gastric effect Effects 0.000 description 15
241000699800 Cricetinae Species 0.000 description 14
241001465754 Metazoa Species 0.000 description 14
239000000284 extract Substances 0.000 description 14
210000004877 mucosa Anatomy 0.000 description 14
230000006870 function Effects 0.000 description 13
230000002297 mitogenic effect Effects 0.000 description 13
208000025865 Ulcer Diseases 0.000 description 12
210000000981 epithelium Anatomy 0.000 description 12
230000012010 growth Effects 0.000 description 12
102000003940 Occludin Human genes 0.000 description 11
108090000304 Occludin Proteins 0.000 description 11
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
239000002953 phosphate buffered saline Substances 0.000 description 11
210000002105 tongue Anatomy 0.000 description 11
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 11
239000013598 vector Substances 0.000 description 11
102400001368 Epidermal growth factor Human genes 0.000 description 10
101800003838 Epidermal growth factor Proteins 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
229940116977 epidermal growth factor Drugs 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
239000002609 medium Substances 0.000 description 9
239000007800 oxidant agent Substances 0.000 description 9
230000001590 oxidative effect Effects 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 8
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 8
108010076504 Protein Sorting Signals Proteins 0.000 description 8
239000003102 growth factor Substances 0.000 description 8
239000003226 mitogen Substances 0.000 description 8
210000002784 stomach Anatomy 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
238000004113 cell culture Methods 0.000 description 7
210000004692 intercellular junction Anatomy 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
230000001681 protective effect Effects 0.000 description 7
230000008439 repair process Effects 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
231100000397 ulcer Toxicity 0.000 description 7
206010015150 Erythema Diseases 0.000 description 6
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
210000002808 connective tissue Anatomy 0.000 description 6
231100000321 erythema Toxicity 0.000 description 6
230000001181 motogenic effect Effects 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
150000007523 nucleic acids Chemical group 0.000 description 6
238000011084 recovery Methods 0.000 description 6
208000022559 Inflammatory bowel disease Diseases 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
206010020718 hyperplasia Diseases 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000010410 layer Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000000746 purification Methods 0.000 description 5
210000004203 pyloric antrum Anatomy 0.000 description 5
230000009467 reduction Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000028327 secretion Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
230000008719 thickening Effects 0.000 description 5
230000024883 vasodilation Effects 0.000 description 5
241000238631 Hexapoda Species 0.000 description 4
206010020649 Hyperkeratosis Diseases 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000013553 cell monolayer Substances 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000004624 confocal microscopy Methods 0.000 description 4
230000001186 cumulative effect Effects 0.000 description 4
210000000805 cytoplasm Anatomy 0.000 description 4
238000005194 fractionation Methods 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
238000013508 migration Methods 0.000 description 4
238000010172 mouse model Methods 0.000 description 4
230000004682 mucosal barrier function Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
241000699673 Mesocricetus auratus Species 0.000 description 3
206010030216 Oesophagitis Diseases 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
241000235648 Pichia Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
102000000591 Tight Junction Proteins Human genes 0.000 description 3
108010002321 Tight Junction Proteins Proteins 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
230000007613 environmental effect Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000035876 healing Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
208000002551 irritable bowel syndrome Diseases 0.000 description 3
210000001985 kidney epithelial cell Anatomy 0.000 description 3
230000004807 localization Effects 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
108091005601 modified peptides Proteins 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
101710194912 18 kDa protein Proteins 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
101710124086 Envelope protein UL45 Proteins 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 2
208000007882 Gastritis Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
102000015728 Mucins Human genes 0.000 description 2
108010063954 Mucins Proteins 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
108091005461 Nucleic proteins Proteins 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
208000007107 Stomach Ulcer Diseases 0.000 description 2
102000011154 Tight junction protein ZO-1 Human genes 0.000 description 2
108050001370 Tight junction protein ZO-1 Proteins 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000005178 buccal mucosa Anatomy 0.000 description 2
244000309466 calf Species 0.000 description 2
125000002843 carboxylic acid group Chemical group 0.000 description 2
230000012292 cell migration Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
206010009887 colitis Diseases 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
210000004922 colonic epithelial cell Anatomy 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000001493 electron microscopy Methods 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
208000006881 esophagitis Diseases 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000001744 histochemical effect Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
210000002490 intestinal epithelial cell Anatomy 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000005012 migration Effects 0.000 description 2
239000000178 monomer Substances 0.000 description 2
229940051875 mucins Drugs 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
230000036407 pain Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010025188 Alcohol oxidase Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
101100407060 Caenorhabditis elegans par-6 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
102000011068 Cdc42 Human genes 0.000 description 1
108050001278 Cdc42 Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010058839 Enteritis infectious Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
101150031828 F2RL2 gene Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
206010056663 Gastric infection Diseases 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
101000817237 Homo sapiens Protein ECT2 Proteins 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
101710141347 Major envelope glycoprotein Proteins 0.000 description 1
206010028034 Mouth ulceration Diseases 0.000 description 1
206010028124 Mucosal ulceration Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
238000007126 N-alkylation reaction Methods 0.000 description 1
102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101150027732 Pard3 gene Proteins 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
244000137852 Petrea volubilis Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100040437 Protein ECT2 Human genes 0.000 description 1
102100021538 Protein kinase C zeta type Human genes 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000375392 Tana Species 0.000 description 1
108010007389 Trefoil Factors Proteins 0.000 description 1
102000007641 Trefoil Factors Human genes 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000009798 acute exacerbation Effects 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000032683 aging Effects 0.000 description 1
-1 alkyl amide Chemical class 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
108010017357 cryptdin 3 Proteins 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000012303 cytoplasmic staining Methods 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
230000006240 deamidation Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013400 design of experiment Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000035622 drinking Effects 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
230000004890 epithelial barrier function Effects 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
210000002599 gastric fundus Anatomy 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
238000003304 gavage Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
LXJXRIRHZLFYRP-UHFFFAOYSA-N glyceraldehyde 3-phosphate Chemical compound O=CC(O)COP(O)(O)=O LXJXRIRHZLFYRP-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
238000011553 hamster model Methods 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000012203 high throughput assay Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000001329 hyperkeratotic effect Effects 0.000 description 1
210000004201 immune sera Anatomy 0.000 description 1
229940042743 immune sera Drugs 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000000266 injurious effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
230000003780 keratinization Effects 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000004678 mucosal integrity Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
108010050991 protein kinase C zeta Proteins 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000011127 radiochemotherapy Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000012508 resin bead Substances 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000004894 snout Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
210000004876 tela submucosa Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
235000021476 total parenteral nutrition Nutrition 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000010361 transduction Methods 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CA2643736A 2005-05-10 2006-05-09 Methods and compositions to treat mucositis Expired - Fee Related CA2643736C (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP05010217.7		2005-05-10
EP05010217A EP1595547A3 (de)	2004-05-11	2005-05-10	Verwendung des Wachstumsfaktors AMP zur Behandlung von gastrointestinalen Schäden und von akutem Nierenversagen
US79017706P	2006-04-07	2006-04-07
US60/790,177		2006-04-07
PCT/US2006/018014 WO2006122162A2 (en)	2005-05-10	2006-05-09	Use of peptides derived from the growth factor amp-18 for the treatment of mucositis

Publications (2)

Publication Number	Publication Date
CA2643736A1 CA2643736A1 (en)	2006-11-16
CA2643736C true CA2643736C (en)	2015-06-23

Family

ID=40140138

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2643736A Expired - Fee Related CA2643736C (en)	2005-05-10	2006-05-09	Methods and compositions to treat mucositis

Country Status (4)

Country	Link
JP (2)	JP5058980B2 (de)
AT (1)	ATE526983T1 (de)
CA (1)	CA2643736C (de)
MX (1)	MX2007013982A (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6734289B2 (en) *	2001-03-29	2004-05-11	The University Of Chicago	Gastrokines and derived peptides including inhibitors
US7629317B2 (en) *	2001-03-29	2009-12-08	The University Of Chicago	Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors

2006
- 2006-05-09 AT AT06770157T patent/ATE526983T1/de not_active IP Right Cessation
- 2006-05-09 JP JP2008511298A patent/JP5058980B2/ja not_active Expired - Fee Related
- 2006-05-09 CA CA2643736A patent/CA2643736C/en not_active Expired - Fee Related
- 2006-05-09 MX MX2007013982A patent/MX2007013982A/es active IP Right Grant
2011
- 2011-11-30 JP JP2011262746A patent/JP2012046547A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ATE526983T1 (de)	2011-10-15
MX2007013982A (es)	2008-03-13
JP5058980B2 (ja)	2012-10-24
CA2643736A1 (en)	2006-11-16
JP2008544959A (ja)	2008-12-11
JP2012046547A (ja)	2012-03-08

Legal Events

Date	Code	Title	Description
2011-04-20	EEER	Examination request
2018-06-20	MKLA	Lapsed	Effective date: 20180509

Publication	Publication Date	Title
CN104147591B (zh)	2017-04-12	Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
KR102373603B1 (ko)	2022-03-14	섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
EP1914310A2 (de)	2008-04-23	Zelldurchlässige Peptidhemmer des JNK-Signaltransduktionsweges
ES2966133T3 (es)	2024-04-18	Proteína de fusión que comprende el factor de crecimiento nervioso y método de preparación y uso de la misma
JP2008106076A (ja)	2008-05-08	ＩＩ型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質
RO117177B1 (ro)	2001-11-30	Proteine recombinante, anti-obezitate, murine şi umane, secvenţă adn, care le codifică, procedeu de producere a proteinei şi conjugat cu acestea
CN105530949A (zh)	2016-04-27	人类受试者中的肌抑素拮抗作用
CA2632544A1 (en)	2007-06-14	Use of myostatin antagonist for treating the effects of hypogonadism
US20100113356A1 (en)	2010-05-06	Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
ES2700149T3 (es)	2019-02-14	Proteínas de fusión de UTI
CN102112148A (zh)	2011-06-29	Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗慢性或非慢性炎性消化病的应用
JP2002526073A (ja)	2002-08-20	新規のヒト生長分化因子のコード配列、そのｄｎａ配列によりコードされるポリペプチド、およびこれらの製造方法。
KR20000010571A (ko)	2000-02-15	신경교세포주-유래신경영양성인자수용체및이를코드하는핵산서열과아미노산서열_
KR20220097921A (ko)	2022-07-08	인터루킨-22의 치료 유도체
KR20170080526A (ko)	2017-07-10	Fgf21 아날로그, fgf21 결합체, 및 이의 용도
AU2006244080B2 (en)	2011-09-08	Use of peptides derived from the growth factor AMP-18 for the treatment of mucositis
CN115916831A (zh)	2023-04-04	包含抗lag-3抗体和il-2的融合蛋白及其用途
US8017576B2 (en)	2011-09-13	Methods and compositions to treat mucositis
KR102221041B1 (ko)	2021-02-25	신증후군 및 관련 병태의 치료 방법
EP1885390B1 (de)	2011-10-05	Verwendung von peptiden aus dem wachstumsfaktors amp-18 zur behandlung von stomatitis
JP7649923B2 (ja)	2025-03-21	ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用
TWI748306B (zh)	2021-12-01	包含人類Lefty A蛋白變體的融合蛋白及其用途
CA2643736A1 (en)	2006-11-16	Methods and compositions to treat mucositis
CN1952129B (zh)	2011-09-21	Angptl4缺失突变体及其应用
CN100480264C (zh)	2009-04-22	一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列